Viral Vitalism

Medicine

Addiction

Evidence-aware explainers on addiction biology, reward circuitry, substance-use behavior, treatment research, and consumer health claims.

1 published articleBuilding this topic
MedicineEarly evidenceGLP-1

GLP-1s, Dopamine, and Addiction: The Substance Use Signal

GLP-1 medications may do more than reduce appetite for food. Early clinical trials, real-world data, and preclinical research suggest they may also affect craving, reward, alcohol intake, and substance-use patterns - but the science is still developing.

16 min readRead->

Related research

Semaglutide AUD Phase 2: Once-Weekly Semaglutide in Adults With Alcohol Use DisorderSemaglutide AUD + Obesity: Once-weekly semaglutide versus placebo in patients with alcohol use disorder and comorbid obesitySemaglutide CUD EHR: Association of semaglutide with reduced incidence and relapse of cannabis use disorder in real-world populationsGLP-1 Addiction Neurobiology Review: GLP-1 analogues in the neurobiology of addiction

Useful source library entries

Once-Weekly Semaglutide in Adults With Alcohol Use DisorderThe role of GLP-1 in addictive disordersGLP-1 analogues in the neurobiology of addictionThe potential role of GLP-1 receptor agonists in substance use disorders

Related topics

MedicineGLP-1Regenerative MedicineSemaglutideTirzepatideWegovy

Vital Signals

Get the weekly health signal without the wellness fog.

A clean weekly brief covering longevity science, fitness, nutrition, medicine, health culture, and the claims worth questioning.

No spam. No miracle claims. Just better health signal.

By subscribing, you agree to receive email from Viral Vitalism. Unsubscribe anytime. See our Privacy Policy.